Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	13/SC/0173	108971	VIABLE: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostrate Cancer Eligible for 1st Line Chemotherapy	Range Agreed	6	8	Date Agreed	16/11/2018	6	6	07/10/2017	Recruitment finished	
2	15/LO/1118	180199	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers	Number Agreed	5	5	Date Agreed	30/06/2025	1	1	18/12/2017	Withdrawn by sponsor	Sponsor closed enrollment to the study because the initial data appeard there was linited or no significant benefit of treatment with GSK525762 as a single agent in subjects
3	14/SC/1161	17382	Prospective,single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Range Agreed	50	100	Date Agreed	31/05/2018	100	100	30/11/2017	Recruitment finished	
4	15/LO/1289	18607	Multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures	Range Agreed	5	8	Date Agreed	31/01/2018	6	6	12/12/2017	Recruitment finished	
5	15/EE/0301	173689	A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and the association with Hemophilia A and its treatment in patients with moderate to severe Hemophilia A.	Range Agreed	10	40	Date Agreed	31/08/2018	41	41	04/12/2017	Recruitment finished	
6	15/WS/0282	18747	Safety & Efficacy of Lenalidomide with MOR00208 in R-R DLBCL Patients	Range Agreed	2	6	Date Agreed	31/10/2017	3	3	31/10/2017	Recruitment finished	
7	15/LO/0781	171789	Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patients	Number Agreed	1	1	Date Agreed	01/11/2017	1	1	01/11/2017	Recruitment finished	
8	16/NW/0238	183403	DRAKO Non-interventional Study	Range Agreed	10	25	Date Agreed	31/12/2017	10	10	31/12/2017	Recruitment finished	
9	17/ES/0030	216486	PHASE IV OPEN LABEL SINGLE GROUP ONE YEAR STUDY OF HOME SELF-INJECTION WITH SAYANA® PRESS IN ADULT WOMEN OF REPRODUCTIVE AGE	Number Agreed	10	10	Date Agreed	20/04/2018	1	1	01/12/2017	Withdrawn by sponsor	Main site reached their target and therefore closed the study earlier than planned
10	16/EM/0007	190428	Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes.	Number Agreed	4	4	Date Agreed	31/12/2018	4	4	02/10/2017	Recruitment finished	
11	16/NS/0070	208445	The HeartFlow ADVANCE Registry: Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE	Range Agreed	3	6	Date Agreed	29/06/2021	4	4	31/10/2017	Recruitment finished	
12	16/LO/0803	204170	Study of MiniMed™ 640G Insulin Pump with SmartGuard™ in prevention of Low Glucose Events in adults with Type 1 diabetes	Number Agreed	7	7	Date Agreed	01/12/2017	0	0	01/12/2017	Withdrawn by sponsor	No patients were recruited and Newcastle was closed as a site by the sponsor
13	16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Number Agreed	4	4	Date Agreed	31/10/2017	1	1	09/10/2017	Recruitment finished	Only one patient from the original study was eligible to continue

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
14	16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	Range Agreed	1	3	Date Agreed	21/12/2017	1	1	13/12/2017	Recruitment finished	
15	17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Range Agreed	3	6	Date Agreed	30/06/2018	0	0	20/11/2017	Withdrawn by sponsor	The sponsor discontinued the tozadenant development program, an investigaional treatment for Parkinson's disease. Based on new inforamtion obtained from the Phase 3 program relating to previously agranulocytosis and associated serious adverse events.
16	16/NE/0387	218683	Amended Clinical Protocol #1 for a Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD).	Number Agreed	7	7	Date Agreed	02/03/2018	7	7	31/10/2017	Recruitment finished	
17	16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Number Agreed	3	3	Date Agreed	31/01/2018	1	1	06/11/2017	Withdrawn by sponsor	Newcastle recruited one patient before the study was closed by the sponsor
18	16/SC/0676	217183	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis	Number Agreed	1	1	Date Agreed	31/10/2017	0	0	31/10/2017	Recruitment finished	The clinical team were actively looking for paients however, they didn't identify any in clinic who fitted the strict eligibilty critera
19	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Number Agreed	1	1	Date Agreed	31/05/2018	1	1	12/10/2017	Recruitment finished	
20	16/WM/0433	215494	A research study to describe the "real world" use of Thrombopoietin-Receptor Agonists (TRAs) in the management of Immune Thrombocytopenia (ITp) in the UK	Number Agreed	10	10	Date Agreed	31/10/2017	10	10	31/10/2017	Recruitment finished	
21	17/NE/0270	231054	Serum sample collection to determine analytical performance characteristics of the ADVIA CENTAUR® Free Beta Human Chorionic Gonadotropin assay	Number Agreed	150	150	Date Agreed	16/02/2018	173	173	19/12/2017	Recruitment finished	
22	16/EE/0357	206501	Opicapone in clinical practice	Range Agreed	4	8	Date Agreed	13/12/2017	4	4	13/12/2017	Recruitment finished	
23	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of multiple sclerosis	Number Agreed	3	3	Date Agreed	27/12/2017	0	0	14/12/2017	Withdrawn by sponsor	Due to fast Global recruitment the sponsor was able to close the study early. No patients were recruited at Newcastle

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
24	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	3	3	Date Agreed	31/12/2017	0	0	31/12/2017	Withdrawn by sponsor	The sponsor closed the arm of the trail that was going to use their microbeads a form of Intra venous placement- worldwide. They are now looking at developing a treatment in partnership with clot retrial equipment to use the microbeads in the inter arterial form
25	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Range Agreed	1	4	Date Agreed	12/12/2017	3	3	12/12/2017	Recruitment finished	
26	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Range Agreed	2	6	Date Agreed	31/05/2018	2	2	12/03/2018	Withdrawn by sponsor	Competitive recruitment by sponsor
27	17/LO/0096	220205	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)	Number Agreed	4	4	Date Agreed	01/04/2018	0	0	08/03/2018	Withdrawn by sponsor	Sponsor closed study early following announcement of voluntary worldwide withdrawal of ZINBRYTA (daclizumab) for relapsing multiple sclerosis.
28	12/LO/1257	105896	UTCPH310: Oral UT-15C for treatment of Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	6	Date Agreed	30/04/2018	7	7	31/12/2017	Recruitment finished	
29	16/EM/0512	215840	A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION–POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA	Range Agreed	1	3	Date Agreed	31/10/2018	1	1	30/03/2018	Recruitment finished	
30	16/NE/0321	211563	A Phase 2, Double-Blind, Placebo-Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome	Range Agreed	14	28	Date Agreed	01/02/2018	22	22	01/02/2018	Recruitment finished	
31	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	20	Date Agreed	01/02/2018	25	25	01/02/2018	Recruitment finished	
32	15/LO/1950	184545	A Randomized Placebo Controlled Phase 2b/3 Study of ABT-414 in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)	Range Agreed	1	5	Date Agreed	20/04/2018	2	2	15/01/2018	Recruitment finished	
33	16/SC/0677	217105	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis	Number Agreed	2	2	Date Agreed	31/10/2017	0	0	31/10/2017	Withdrawn by sponsor	No patients was identified due to the strict eligibility criteria

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
34	15/NE/0143	174391	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Range Agreed	2	3	Date Agreed	17/11/2017	2	2	17/11/2017	Recruitment finished	
35	16/SC/0530	213306	Evaluating the tolerance, compliance, acceptability and safety of Ketocal 2.5:1 LQ, a nutritionally complete liquid feed for use as part of the Ketogenic Diet in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated	Number Agreed	3	3	Date Agreed	13/12/2018	3	3	30/03/2018	Recruitment finished	
36	17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Number Agreed	3	3	Date Agreed	30/01/2019	4	4	31/01/2018	Recruitment finished	
37	16/WM/0409	204629	Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Range Agreed	6	10	Date Agreed	15/01/2018	7	7	15/01/2018	Recruitment finished	
38	17/LO/1147	222154	Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2 (ECZema TRAlokinumab trial no. 2)	Number Agreed	6	6	Date Agreed	01/07/2018	7	7	23/03/2018	Recruitment finished	
39	16/WM/0471	215399	An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)	Range Agreed	2	4	Date Agreed	15/07/2018	4	4	30/03/2018	Recruitment finished	
40	17/WS/0165	226413	A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 Infection and Aspartate aminotransferase to Platelet Ratio Index (APRI) ≤ 1	Range Agreed	2	6	Date Agreed	24/01/2018	5	5	24/01/2018	Recruitment finished	
41	17/NI/0367	237110	A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	7	7	Date Agreed	05/05/2020	7	7	16/03/2018	Recruitment finished	
42	17/SC/0028	218036	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Number Agreed	4	4	Date Agreed	30/03/2018	1	1	26/02/2018	Recruitment finished	Competitive recruitment by sponsor meant the study closed early than planned

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
43	15/LO/1480	186764	Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns (HOLOCORE)	Range Agreed	3	5	Date Agreed	31/01/2019	5	5	30/05/2018	Recruitment finished	
44	17/NE/0019	212701	SharkCore biopsy needle versus standard FNA needle in the diagnosis of solid pancreatic masses a randomised controlled cross-over trial of EUS guided tissue acquisition - The SharkBITE study	Number Agreed	108	108	Date Agreed	31/05/2018	108	108	31/05/2018	Recruitment finished	
45	16/WM/0473	213847	A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Range Agreed	3	11	Date Agreed	26/02/2018	9	9	26/02/2018	Recruitment finished	
46	15/WA/0465	189501	Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds	Number Agreed	10	10	Date Agreed	19/06/2018	2	2	19/06/2018	Withdrawn by sponsor	Sponsor withdrew study due to urgent safety measures
47	16/YH/0186	200765	A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)	Number Agreed	5	5	Date Agreed	30/04/2018	2	2	30/04/2018	Withdrawn by sponsor	Sponsor closed the study due to high screen failure rates
48	15/SC/0659	189114	A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer's Dementia	Range Agreed	3	6	Date Agreed	31/08/2018	0	0	17/05/2018	Withdrawn by sponsor	Sponsor took the decision to close the study because of the benefit-risk was no longer favourable to continue development of atabecestat in individuals with preclinical sporadic AD
49	16/ES/0100	195249	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (CF) Being Treated for an Exacerbation of CF-associated Lung Disease	Range Agreed	1	6	Date Agreed	31/03/2018	6	6	31/03/2018	Recruitment finished	
50	15/SS/0148	181087	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab BIIB037 in Subjects with Early Symptomatic Alzheimer's Disease	Number Agreed	3	3	Date Agreed	28/02/2018	3	3	28/02/2018	Recruitment finished	
51	16/EM/0436	213166	SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)	Number Agreed	1	1	Date Agreed	28/02/2018	0	0	28/02/2018	Withdrawn by sponsor	Recruitment was met globally before the Nuth site was able to consent a patient

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
52	16/EE/0358	212839	A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infection	Number Agreed	3	3	Date Agreed	13/04/2018	3	3	13/04/2018	Recruitment finished	
53	16/LO/1589	200691	A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WELL DIFFERENTIATED, METASTATIC AND/OR UNRESECTABLE TYPICAL OR ATYPICAL LUNG NEUROENDOCRINE TUMORS	Number Agreed	4	4	Date Agreed	30/06/2018	0	0	30/06/2018	Withdrawn by sponsor	Despite all efforts and resources invested to overcome recruitment challenges the sponsor toke the decision to end patient enrollment in the study
54	16/WM/0507	218607	A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered adalimumab monotherapy in patients with active psoriatic arthritis	Number Agreed	2	2	Date Agreed	17/04/2018	2	2	17/04/2018	Recruitment finished	
55	17/EE/0071	201502	Direct Implantation of the SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System (IDS) with Bioresorbable Drug Carrier Technology The DIRECT III Post Market Study	Range Agreed	3	50	Date Agreed	31/12/2017	15	15	31/12/2017	Recruitment finished	
56	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	Range Agreed	6	12	Date Agreed	28/04/2018	6	6	28/04/2018	Recruitment finished	
57	17/SC/0294	224828	Title: A Phase III Randomised Study to Investigate the Efficacy and Safety of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline/Nab-paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer	Number Agreed	3	3	Date Agreed	12/06/2018	3	3	12/06/2018	Recruitment finished	
58	17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Range Agreed	2	3	Date Agreed	30/01/2019	2	2	30/01/2018	Recruitment finished	
59	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	4	4	26/06/2018	Recruitment finished	
60	17/WM/0246	220487	Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting.	Number Agreed	5	5	Date Agreed	31/05/2018	5	5	31/05/2018	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
61	17/LO/1461	230430	A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals' investigational vaccine GSK3277511A when administered intramuscularly according to a 0, 2 months schedule in COPD patients aged 40 to 80 years with a previous history of acute exacerbation (AECOPD).	Range Agreed	3	10	Date Agreed	08/06/2018	3	3	08/06/2018	Recruitment finished	
62	18/LO/0112	238122	A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years	Range Agreed	1	6	Date Agreed	31/05/2018	1	1	16/05/2018	Recruitment finished	
63	14/WS/1113	153352	A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira®(Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD)	Number Agreed	3	3	Date Agreed	30/04/2020	3	3	01/03/2018	Recruitment finished	
64	15/WM/0363	184648	A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, MulticenterStudy Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis.	Number Agreed	2	2	Date Agreed	30/06/2018	2	2	30/06/2018	Recruitment finished	
65	15/YH/0483	191668	Single Arm Study to Assess the Efficacy of UVADEX (methoxsalen) Sterile Solution in conjunction with the Therakos CELLEX Photopheresis system in Pediatric Patients with steroid-refractory Acute Graft versus Host Disease (aGvHD)	Number Agreed	1	1	Date Agreed	30/04/2018	1	1	30/04/2018	Recruitment finished	
66	17/LO/1571	230731	A Prospective observational study of paediatric patients affected by haematological disorders treated with matched unrelated donor stem cell transplant	Range Agreed	2	5	Date Agreed	01/07/2018	4	4	30/06/2018	Recruitment finished	
67	14/WM/0182	153362	A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren's syndrome	Range Agreed	3	7	Date Agreed	30/04/2018	5	5	30/04/2018	Recruitment finished	
68	17/EE/0291	203703	A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma	Number Agreed	2	2	Date Agreed	01/02/2019	0	0	13/07/2018	Withdrawn by sponsor	Rare cancer study where the sponsor changed the protocol that excluded patients who were suitable for auto or all stem cell transplant, which greatly reduced the portential to recruit patients. The sponsor decided to withdraw the study earlier than expected

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
69	17/EE/0079	220827	A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamise/ Azathioprine	Number Agreed	2	2	Date Agreed	30/12/2018	0	0	04/07/2018	Withdrawn by sponsor	This study dealt with a rare disease and unfortunately no suitable patient fulfilled the eligibility criteria. The sponsor met their criteria globally and closed the study earlier than expected
70	13/NI/0123	135437	MILES UK: Post Marketing, Multicenter, Single Arm, Observational Clinical Registry to Evaluate Safety and Efficacy of BioMime Sirolimus Eluting Stent System In All Comers Real World Population With Coronary Artery Stenosis in United Kingdom	Range Agreed	20	45	Date Agreed	31/07/2018	31	31	31/07/2018	Recruitment finished	
71	14/SC/1366	135118	A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy (EPOCH)	Range Agreed	4	6	Date Agreed	01/09/2018	4	4	01/09/2018	Recruitment finished	
72	15/SW/0194	185459	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease	Number Agreed	8	8	Date Agreed	20/06/2018	4	4	08/06/2018	Withdrawn by sponsor	Competitive recruitment by sponsor meant the study reseached its target sooner that expected
73	16/LO/0908	202601	A phase 3, placebo controlled, double-blind, randomized, clinical study to determine efficacy, safety and tolerability of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial hypertension (PAH): INOvation-1	Range Agreed	1	2	Date Agreed	07/08/2018	1	1	07/08/2018	Recruitment finished	
74	16/SC/0436	211806	A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy	Range Agreed	1	2	Date Agreed	24/08/2018	1	1	24/08/2018	Recruitment finished	
75	15/WS/0170	184797	Non-interventional study on Edoxaban treatment in routine clinical practice in patients with Venous Thromboembolism in Europe	Number Agreed	6	6	Date Agreed	15/09/2018	2	2	10/09/2018	Recruitment finished	The study did not hit the target due to the fact that assistance was needed for EAU for idenfifying patients that were put ont Edoxaban for DVTs. The sponsor felt it was too late to reduce the target
76	17/LO/0232	220795	A Three-Part Open Label Titration, Open Label Randomized Crossover, and Double Observer Single-Blind, Superiority Trial of APL-130277 compared to S.C. Apomorphine in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations	Number Agreed	4	4	Date Agreed	04/09/2018	0	0	28/08/2018	Withdrawn by sponsor	Due to several changes to the protocol the sponsor decided to withdraw the study in line with EMA recommendations

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
77	17/NE/0078	221507	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg after 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid.	Range Agreed	2	5	Date Agreed	29/06/2018	2	2	29/06/2018	Recruitment finished	
78	17/LO/0402	209419	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY	Number Agreed	3	3	Date Agreed	01/09/2019	0	0	12/07/2018	Withdrawn by host	All avenues were exhausted by the team to find potential recruitment to this study. It was decided to close the site at Newcastle
79	17/NE/0020	218494	A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjögren's syndrome.	Number Agreed	3	3	Date Agreed	31/08/2019	3	3	28/08/2018	Recruitment finished	
80	17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT™|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Range Agreed	2	10	Date Agreed	31/12/2018	0	0	28/08/2018	Withdrawn by sponsor	Study was withdrawn by sponsor due to lack of study recruitment and enrollment at Newcastle
81	17/EE/0038	217456	A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF-α INHIBITORS	Range Agreed	1	2	Date Agreed	30/06/2018	0	0	07/06/2018	Withdrawn by host	All avenues were exhausted by the team to find potential recruitment to this study. It was decided to close the site and Newcastle
82	17/SC/0232	220550	PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL	Range Agreed	2	4	Date Agreed	27/09/2018	0	0	27/09/2018	Withdrawn by sponsor	The study was withdrawn by the sponsor due to objective responses observed ian Arm A and Arm B
83	16/EM/0081	192524	Clinical Efficacy & Safety of AP CD/LD in Fluctuating PD	Range Agreed	6	8	Date Agreed	10/08/2018	1	1	10/08/2018	Withdrawn by sponsor	Due to Competitive recruitment the sponsor reached their enrollment target and closed all sites
84	17/EE/0297	225586	A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS	Number Agreed	2	2	Date Agreed	28/09/2018	2	2	28/09/2018	Recruitment finished	
85	14/YH/0140	147851	Persona Outcomes Led Assessment Research in Total Knee Arthroplasty (POLAR)	Range Agreed	50	75	Date Agreed	31/05/2018	76	76	31/05/2018	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
86	17/YH/0387	230570	A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer	Number Agreed	3	3	Date Agreed	31/08/2018	4	4	22/08/2018	Recruitment finished	
87	17/YH/0388	235066	A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Range Agreed	5	10	Date Agreed	15/08/2018	8	8	31/07/2018	Recruitment finished	
88	17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies (AFFINITY)	Number Agreed	2	2	Date Agreed	14/06/2019	1	1	21/09/2018	Recruitment finished	The study closed early due to competitive recruitment
89	17/NE/0351	235420	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF PROSTATE CANCER	Number Agreed	30	60	Date Agreed	31/10/2018	61	61	07/08/2018	Recruitment finished	
90	17/NE/0117	222778	A Phase 2b, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with BPS804	Range Agreed	1	4	Date Agreed	30/09/2018	2	2	30/09/2018	Recruitment finished	
91	15/SC/0295	177196	An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (ORZORA)	Number Agreed	2	2	Date Agreed	30/09/2018	1	1	30/09/2018	Recruitment finished	The study required patients to have specific mutation in their tumour to be eligible for the trial – in total the team screened 20 patients and only found one eligible with the mutations required
92	18/NE/0104	241180	A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Number Agreed	1	1	Date Agreed	31/07/2018	1	1	21/07/2018	Recruitment finished	
93	17/WS/0146	219953	Ciclosporin 1mg/ml eye drop emulsion (Ikervis®) for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes: Clinical effectiveness, tolerability and safety in a real world setting	Number Agreed	5	5	Date Agreed	30/09/2018	1	1	30/09/2018	Recruitment finished	All avenues were exhausted by the team to find potential participants to this study

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
94	15/LO/0618	170965	Phase I/II study of CaspaCIDe T cells from an HLA-partially matched family donor after negative selection of TCRab+Tcells in pediatric patients affected by hematological disorders	Number Agreed	10	10	Date Agreed	09/02/2018	15	15	09/02/2018	Recruitment finished	
95	16/NE/0370	214375	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid steroids.	Number Agreed	5	5	Date Agreed	31/12/2018	5	5	30/09/2018	Recruitment finished	
96	18/NW/0006	237093	Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis	Number Agreed	1	1	Date Agreed	30/06/2019	1	1	31/08/2018	Recruitment finished	
97	17/LO/0736	225746	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy	Number Agreed	3	3	Date Agreed	01/08/2018	5	5	01/08/2018	Recruitment finished	
98	17/EE/0255	227279	A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN PATIENTS WITH CHRONIC REFRACTORY COUGH	Number Agreed	3	3	Date Agreed	30/09/2018	3	3	30/09/2018	Recruitment finished	